$XERS The excerpt below is from a write up on Halozyme. The writer was pointing out that Merck is converting its lower strength version of Keytruda to subcutaneous in house, but that they would need help with the higher strength formulation. Remember Merck is working with us to develop “ultra high concentration” subcutaneous formulations. Could this ultra high formulation be for Keytruda’s 500 mg dose product?
1
2
2 Likes